Nasus Pharma (NSRX) Company Presentation summary

Strategic positioning and technology

• Focuses on powder-based intranasal drug delivery for emergency medical conditions, leveraging proprietary Nasax® technology for enhanced absorption and longer shelf-life.

• Lead product NS002 targets anaphylaxis with a needle-free, convenient alternative to epinephrine autoinjectors.

• Platform validated by successful Phase 3 results for intranasal naloxone (NS001), now available for partnering.

• Strong intellectual property protection extends to 2038 and beyond in multiple jurisdictions.

• Experienced leadership team with deep expertise in life sciences, pharma, and venture capital.

Clinical development and results

• NS002 demonstrated faster and higher maximal epinephrine absorption than EpiPen in pilot and Phase 2 studies.

• Phase 2: 91% of subjects reached therapeutic plasma threshold at 6 minutes with NS002 4mg, versus 55% for EpiPen.

• Comparable pharmacodynamic activity to EpiPen with no serious adverse events and good tolerability.

• NS001 (naloxone) delivered faster and higher absorption than Narcan in Phase 3, supporting platform efficacy.

• Additional Phase 2 studies for NS002 planned for Q4 2025, pivotal and pediatric studies to follow in 2026.

Market opportunity and competitive landscape

• Anaphylaxis affects 1–3% globally; US market includes 40M type 1 allergy patients and $2.3B epinephrine market.

• Many at-risk patients remain untreated or do not carry/refill epinephrine, highlighting unmet need.

• Needle-free epinephrine products could expand market access and address patient barriers like needle phobia and device bulk.

• NS002 shows faster absorption and higher early plasma concentrations compared to other intranasal competitors.

• Robust pipeline includes candidates for nausea, poisoning, seizures, and opioid overdose, supporting long-term growth.